Regenerative Medicine
Ischemic Injury
Provasculon Inc. is developing novel protein therapies that promote the repair of vascular tissue, help organs heal and regenerate function by recruiting and activating stem cells in areas of ischemic damage caused by myocardial infarction, chronic heart failure, and peripheral vascular disease. These therapies may also have the potential to recruit and activate stem cells that promote tissue repair in stroke patients and those suffering from chronic wounds that do not heal.
Cardiovascular disease
Coronary heart disease is responsible for 1 in 5 deaths in the US, and is the 3rd leading cause of death (after AIDS and respiratory infections) in the developing world. Approximately half of patients in western countries who survive a heart attack progress to chronic heart failure. Chronic progressive heart failure greatly diminishes quality of life. It affects 5 million people in the US alone, is the leading cause of hospitalization in patients over 65 years of age, and although some patients with chronic heart failure survive many years, overall,1 in 10 patients with chronic heart failure die each year. Peripheral vascular disease is often concomitant with coronary heart disease and diabetes, affecting over 25 million people in the US and Europe; up to 10% of patients suffering with critical limb ischemia, the most severe form of the disease, face invasive surgeries and amputation. Current therapies for these conditions neither halt nor reverse progression of disease.